On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Chester County Futures (CCF), in collaboration with Globus Medical, recently provided a transformative learning experience ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...